Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma

被引：34

作者：

Dhakras, Purabi ^{[1
]}

Uboha, Nataliya ^{[2
,3
,4
]}

Horner, Vanessa ^{[1
,5
]}

Reinig, Erica ^{[1
]}

Matkowskyj, Kristina A. ^{[1
,3
,4
]}

机构：

[1] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA

[2] Univ Wisconsin, Dept Med, Div Hematol Med Oncol & Palliat Care, Madison, WI USA

[3] UW Carbone Canc Ctr, Madison, WI USA

[4] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA

[5] Wisconsin State Lab Hyg, Madison, WI USA

来源：

TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 5卷

关键词：

Human epidermal growth factor receptor 2 (HER2); microsatellite instability (MSI); program death-ligand 1 (PD-L1); DNA MISMATCH REPAIR; SHORT-TERM PROGNOSIS; CELL LUNG-CANCER; MICROSATELLITE INSTABILITY; GENE AMPLIFICATION; FAMILIAL PREDISPOSITION; INTERNATIONAL CRITERIA; INSTITUTE WORKSHOP; PD-L1; EXPRESSION; C-ERBB-2; PROTEIN;

D O I：

10.21037/tgh.2020.01.08

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Esophageal and gastric adenocarcinomas are frequently diagnosed at an advanced stage and have a dismal prognosis. Even in patients with potentially curative cancer, nearly 50% will develop recurrent disease despite aggressive treatments. A number of biomarkers currently guide treatment decisions for patients with esophageal and gastric adenocarcinoma and include human epidermal growth factor receptor 2 (HER2) amplification, mismatch repair deficiency/microsatellite instability (dMMR/MSI-H) and program death-ligand 1 (PD-L1) expression. This review will focus on the function, testing and FDA-approved targeted therapies for HER2, dMMR/MSI-H and PD-L1. In addition, a number of novel targets in esophageal and gastric cancer are being studied in clinical trials. Neurotrophic-tropomyosin receptor kinase (NTRK), claudin-18 (CLDN18)/Rho GTPase activating protein 26 (ARHGAP26) gene fusion, fibroblast growth factor receptor (FGFR), lymphocyte-activation gene 3 (LAG3) and T cell immunoglobulin and mucin-domain containing-3 (TIM3) will be briefly reviewed. Despite several biomarkers used in the selection of treatment therapies, treatment outcomes remain poor. Future research efforts will focus on the identification of new biomarkers, moving existing biomarkers into earlier lines of therapy, and evaluating new combinations of existing biomarkers and therapies.

引用

页数：12

共 78 条

[51] A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer [J].

Sahin, Ugur ;

Schuler, Martin ;

Richly, Heike ;

Bauer, Stefan ;

Krilova, Anna ;

Dechow, Tobias ;

Jerling, Markus ;

Utsch, Magdalena ;

Rohde, Christoph ;

Dhaene, Karl ;

Huber, Christoph ;

Tuereci, Ozlem .

EUROPEAN JOURNAL OF CANCER, 2018, 100 :17-26

[52]

SAKAI K, 1986, JNCI-J NATL CANCER I, V77, P1047

[53] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J].

Shitara, Kohei ;

Ozguroglu, Mustafa ;

Bang, Yung-Jue ;

Di Bartolomeo, Maria ;

Mandala, Mario ;

Ryu, Min-Hee ;

Fornaro, Lorenzo ;

Olesinski, Tomasz ;

Caglevic, Christian ;

Chung, Hyun C. ;

Muro, Kei ;

Goekkurt, Eray ;

Mansoor, Wasat ;

McDermott, Raymond S. ;

Shacham-Shmueli, Einat ;

Chen, Xinqun ;

Mayo, Carlos ;

Kang, S. Peter ;

Ohtsu, Atsushi ;

Fuchs, Charles S. .

LANCET, 2018, 392 (10142) :123-133

[54] Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer [J].

Shu, Yang ;

Zhang, Weihan ;

Hou, Qianqian ;

Zhao, Linyong ;

Zhang, Shouyue ;

Zhou, Jiankang ;

Song, Xiaohai ;

Zhang, Yan ;

Jiang, Dan ;

Chen, Xinzu ;

Wang, Peiqi ;

Xia, Xuyang ;

Liao, Fei ;

Yin, Dandan ;

Chen, Xiaolong ;

Zhou, Xueyan ;

Zhang, Duyu ;

Yin, Senlin ;

Yang, Kun ;

Liu, Jianping ;

Fu, Leilei ;

Zhang, Lan ;

Wang, Yuelan ;

Zhang, Junlong ;

An, Yunfei ;

Cheng, Hua ;

Zheng, Bin ;

Sun, Hongye ;

Zhao, Yinglan ;

Wang, Yongsheng ;

Xie, Dan ;

Ouyang, Liang ;

Wang, Ping ;

Zhang, Wei ;

Qiu, Meng ;

Fu, Xianghui ;

Dai, Lunzhi ;

He, Gu ;

Yang, Hanshuo ;

Cheng, Wei ;

Yang, Li ;

Liu, Bo ;

Li, Weimin ;

Dong, Biao ;

Zhou, Zongguang ;

Wei, Yuquan ;

Peng, Yong ;

Xu, Heng ;

Hu, Jiankun .

NATURE COMMUNICATIONS, 2018, 9

[55] Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer [J].

Singh, Prabhsimranjot ;

Toom, Sudhamshi ;

Huang, Yiwu .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10

[56] Mismatch Repair Deficiency, Microsatellite Instability, and Survival An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial [J].

Smyth, Elizabeth C. ;

Wotherspoon, Andrew ;

Peckitt, Clare ;

Gonzalez, David ;

Hulkki-Wilson, Sanna ;

Eltahir, Zakaria ;

Fassan, Matteo ;

Rugge, Massimo ;

Valeri, Nicola ;

Okines, Alicia ;

Hewish, Madeleine ;

Allum, William ;

Stenning, Sally ;

Nankivell, Matthew ;

Langley, Ruth ;

Cunningham, David .

JAMA ONCOLOGY, 2017, 3 (09) :1197-1203

[57] Evaluation of tumor microsatellite instability using five quasi monomorphic mononucleotide repeats and pentaplex PCR [J].

Suraweera, N ;

Duval, A ;

Reperant, M ;

Vaury, C ;

Furlan, D ;

Leroy, K ;

Seruca, R ;

Iacopetta, B ;

Hamelin, R .

GASTROENTEROLOGY, 2002, 123 (06) :1804-1811

[58]

Tabernero J, 2019, 2019 ASCO ANN M JUN

[59]

Tanaka Atsushi, 2018, Oncotarget, V9, P29336, DOI 10.18632/oncotarget.25464

[60] Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab [J].

Tanner, M ;

Hollmén, M ;

Junttila, TT ;

Kapanen, AI ;

Tommola, S ;

Soini, Y ;

Helin, H ;

Salo, J ;

Joensuu, H ;

Sihvo, E ;

Elenius, K ;

Isola, J .

ANNALS OF ONCOLOGY, 2005, 16 (02) :273-278

← 1 2 3 4 5 6 7 8 →